Allos Therapeutics has reported successful clinical results from the PROPEL trial of single-agent Folotyn (pralatrexate injection), used as a second-line treatment for patients with relapsed or refractory peripheral T-cell lymphoma.

The study involved 115 patients and showed that the drug was well-tolerated and safe in peripheral T-cell lymphoma patients.

The findings from the study also reported that the drug demonstrated an improved median duration of response and progression-free survival rate.

The adverse events associated with the drug include, thrombocytopenia, nausea, fatigue, pyrexia, mucositis, sepsis, febrile neutropenia, dehydration and dyspnea.